SpringerProtocols: Abstract: 9. Measurement of Changes in Apoptosis and Cell Cycle Regulatory Kinase Cdk2

9. Measurement of Changes in Apoptosis and Cell Cycle Regulatory Kinase Cdk2

By: Gabriel Gil-Gómez²

Abstract

Full Text

Download PDF (140K)

Many cell cycle regulatory proteins have been shown to be able to regulate cell death. Activation of Cdk2 has been shown to be necessary for the apoptosis of quiescent cells such as thymocytes, neurons, and endothelial cells. This activation is stimulus-specific because it occurs in glucocorticoid and DNA damage-induced but not in CD95-induced apoptosis in thymocytes. Apoptotic Cdk2 activation is controlled by apoptosis regulatory proteins like p53 and Bcl2 family members and correlates with degradation of its inhibitors p21^Cip1 and p27^Kip1 by activated caspases. Methods for measuring Cdk2 changes in activity in quiescent cells undergoing apoptosis are detailed in this chapter.

Affiliation(s): (2) Institut Municipal d’Investigació Mè dica i Universitat Pompeu Fabra, Barcelona, Spain

Book Title: Apoptosis Methods and Protocols

Series: Methods in Molecular Biology | Volume: 282 | Pub. Date: May-20-2004 | Page Range: 131-144 | DOI: 10.1385/1-59259-812-9:131

Subject: Cell Biology

Key Words: Cdk2 - apoptosis - cell cycle - kinase - quiescent cells

References

Download References

1.	Guo, M. and Hay, B. A. (1999) Cell proliferation and apoptosis. Curr. Opin. Cell Biol. 11, 745–752.

2.	Tsai, L. H., Delalle, I., Caviness, V. S., Jr., Chae, T., and Harlow, E. (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419–423.

3.	Norbury, C. and Nurse, P. (1992) Animal cell cycles and their control. Annu.Rev.Biochem. 61, 441–470.

4.	Sherr, C. J. and Roberts, J. M. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501–1512.

5.	Morgan, D. O. (1995) Principles of CDK regulation. Nature 374, 131–134.

6.	Strasser, A., Huang, D. C., and Vaux, D. L. (1997) The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim. Biophys. Acta, 1333, F151–F178.

7.	Kwiatkowska, K. and Sobota, A. (1999) Signaling pathways in phagocytosis. Bioessays 21, 422–431.

8.	Fadok, V. A., Bratton, D. L., Rose, D. M., Pearson, A., Ezekewitz, R. A., and Henson, P. M. (2000) A receptor for phosphatidylserinespecific clearance of apoptotic cells. Nature 405, 85–90.

9.	Levine, A. J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323–331.

10.	Brady, H. J., Gil-Gomez, G., Kirberg, J., and Berns, A. J. (1996) Bax alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J. 15, 6991–7001.

11.	Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko, A. V., and Boldin, M. P. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu.Rev.Immunol. 17, 331–367.

12.	Chao, D. T. and Korsmeyer, S. J. (1998) BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16, 395–419.

13.	Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 68, 383–424.

14.	Brady, H. J. and Gil-Gomez, G. (1999) The cell cycle and apoptosis. Results Probl. Cell Differ. 23, 127–144.

15.	Gil-Gomez, G., Berns, A., and Brady, H. J. (1998) A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J. 17, 7209–7218.

16.	Levkau, B., Koyama, H., Raines, E. W., Clurman, B. E., Herren, B., Orth, K., Roberts, J. M., and Ross, R. (1998) Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol. Cell 1, 553–563.

17.	Sheaff, R. J. (1997) Regulation of mammalian cyclin-dependent kinase 2. Methods Enzymol. 283, 173–193.

18.	Phelps, D. E. and Xiong, Y. (1997) Assay for activity of mammalian cyclin D-dependent kinases CDK4 and CDK6. Methods Enzymol. 283, 194–205.

19.	Azzi, L., Meijer, L., Ostvold, A. C., Lew, J., and Wang, J. H. (1994) Purification of a 15-kDa cdk4-and cdk5-binding protein. J. Biol. Chem. 269, 13,279–13,288.

20.	Zhao, J., Dynlacht, B., Imai, T., Hori, T., and Harlow, E. (1998) Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes Dev. 12(4), 456–461.

21.	Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J., and Pavletich, N. P. (1995) Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376, 313–320.

22.	Lauper, N., Beck, A. R., Cariou, S., Richman, L., Hofmann, K., Reith, W., et al. (1998) Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene 17, 2637–2643.

23.	Mok, C. L., Gil-Gomez, G., Williams, O., Coles, M., Taga, S., Tolaini, M., et al. (1999) Bad can act as a key regulator of T cell apoptosis and T cell development. J. Exp. Med. 189, 575–586.

24.	Norbury, C., MacFarlane, M., Fearnhead, H., and Cohen, G. M. (1994) Cdc2 activation is not required for thymocyte apoptosis. Biochem. Biophys. Res. Commun. 202, 1400–1406.

25.	Gordon, J. A. (1991) Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 201, 477–482.

Comments (Loading...)

Post comment/View all comments